Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02864342 · ClinicalTrials.gov registry record · Phase 4
Adherence Study in COPD Patients
A Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 138
- Enrollment target
- 8
- Study locations
NCT02864342: Completed Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca.
NCT02864342 is a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD) that has completed, run by AstraZeneca. The registered enrollment target is 138 participants, below the 647-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (79% lower). The trial reports 8 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02864342, a Phase 4 study of Chronic Obstructive Pulmonary Disease (COPD), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 138 participants
- Enrollment target
- 8
- Study locations
Study Summary
A randomized clinical study to assess the impact of Symbicort® pMDI medication reminders on adherence in COPD patients
Primary Outcome
The mean number of adherent sets of Symbicort puffs per day for each group, over an average of 26 weeks was calculated. An adherent set of puffs was defined as exactly 2 sets of 2 Symbicort puffs per day. The 2 puffs that constitute a set must have been taken within 60 minutes of each other. A mean of 2.00 sets would be equal to 100% adherence (2 sets of 2 puffs). Subjects who did not take exactly 2 sets of 2 puffs on any given day throughout their device time on study were considered non-adhere
Conditions Studied
Interventions
- DEVICE Arm 1: BreatheMate device with application
- DEVICE Arm 2: BreatheMate device without application
Study Locations (8)
Florida
- Research Site - Clearwater
- Research Site - Tampa
Pennsylvania
- Research Site - Downingtown
- Research Site - Philadelphia
New Jersey
- Research Site - Marlton
New York
- Research Site - Brooklyn
North Carolina
- Research Site - Charlotte
South Carolina
- Research Site - Spartanburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 138 participants |
| Start Date | 2016-08-12 |
| Est. Completion | 2017-10-31 |
| Phase | Phase 4 |
What the finished NCT02864342 record still lists
NCT02864342 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 36 other Chronic Obstructive Pulmonary Disease (COPD) trials with a reported enrollment target (79% lower).
The record links to 1 condition, with Chronic Obstructive Pulmonary Disease (COPD) appearing as the primary indexed condition, and to 2 interventions - of which Arm 1: BreatheMate device with application is the first listed.
NCT02864342 lists 8 locations in 6 states (Florida, Pennsylvania, New Jersey).
Frequently Asked Questions
What is clinical trial NCT02864342 about?
NCT02864342 is a clinical study titled "Adherence Study in COPD Patients". A randomized clinical study to assess the impact of Symbicort® pMDI medication reminders on adherence in COPD patients
What is the current status of trial NCT02864342?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 138 participants. The study started on 2016-08-12. Estimated completion is 2017-10-31.
What conditions does trial NCT02864342 study?
This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease (COPD).
What interventions are being tested in trial NCT02864342?
The interventions under investigation include: Arm 1: BreatheMate device with application (DEVICE), Arm 2: BreatheMate device without application (DEVICE).
Who is sponsoring clinical trial NCT02864342?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02864342 being conducted?
This trial has 8 study locations across Florida, New Jersey, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Obstructive Pulmonary Disease (COPD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02864342's enrollment target sits among peer trials
138 24th of 36 higher than 13 of 36 other Chronic Obstructive Pulmonary Disease (COPD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Obstructive Pulmonary Disease (COPD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Clinical Study to Investigate if a Single Dose of an Approved Drug Product (Glycopyrrolate Inhalation Solution) Reduces Trapped Air in the Lungs of Participants With Chronic Obstructive Pulmonary Disease.
COMPLETED · Phase 4
-
Collection of Airway, Blood and/or Urine Specimens From Subjects for Research Studies
RECRUITING
-
Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD
RECRUITING · Phase 2
-
Multi-Center Clean Air Randomized Controlled Trial in COPD
RECRUITING · Phase 3
-
A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 3
-
A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04402788 · 138 participants · Phase 2
Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial
- NCT04883255 · 138 participants · Early Phase 1
Cannabis Use, Cognition, and the Endocannabinoid System in HIV
- NCT05620784 · 138 participants · Phase 3
Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP
- NCT05832086 · 138 participants · Phase 2
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI